Metabolic & Weight Research
Retatrutide 15mg
Retatrutide 15mg
Three metabolic receptors. One frontier research molecule.
Triple-pathway research across GIP, GLP-1 and glucagon signalling—the combination driving next-generation interest in appetite, glucose and energy expenditure.
- Documentation
- Check batch record
- Availability
- In stock
For qualified laboratory research only · Not for human or veterinary use
Why researchers choose it
Retatrutide is a single investigational molecule designed to activate GIP, GLP-1 and glucagon receptors, opening a three-pathway view of satiety, glycaemic signalling and energy expenditure.
Research focus
- GIP, GLP-1 and glucagon receptor activation
- Appetite and satiety signalling
- Glucose and energy-expenditure research
Evidence snapshot
The molecule reported positive Phase 3 topline results in 2026 but remains unapproved. This catalogue vial is not Lilly trial material, and no equivalence to a clinical-trial formulation is claimed.
Best suited to
For qualified comparative research into multi-receptor metabolic signalling.
Research focus describes published study domains, not a guaranteed outcome. No human or veterinary dosing, reconstitution or administration instructions are supplied.
Related research compounds
Metabolic & Weight10mg
A supplier-named formulation reserved for composition, identity and formulation research; exact ingredients must be established from the matching lot record.
Metabolic & Weight10mg
Dual-pathway metabolic research built around GIP and GLP-1 signalling, with established relevance to appetite, glucose and energy-balance pathways.